Q3 EPS Estimates for Ovid Therapeutics Increased by B. Riley

Key Points

• B. Riley has raised its Q3 2025 EPS estimate for Ovid Therapeutics from ($0.16) to ($0.12), maintaining a "Buy" rating with a target price of $3.00.
• Ovid Therapeutics reported a net revenue of $6.27 million for the last quarter, exceeding expectations significantly.
• Institutional investors currently own 72.24% of Ovid Therapeutics' stock, indicating strong interest from significant financial players.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - B. Riley boosted their Q3 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a report released on Wednesday, August 13th. B. Riley analyst M. El-Saadi now forecasts that the company will earn ($0.12) per share for the quarter, up from their previous forecast of ($0.16). B. Riley currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. B. Riley also issued estimates for Ovid Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at ($0.81) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.10. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%.The firm had revenue of $6.27 million for the quarter, compared to analyst estimates of $0.09 million.

A number of other brokerages have also recently issued reports on OVID. HC Wainwright decreased their target price on Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating for the company in a report on Tuesday, May 27th. William Blair upgraded shares of Ovid Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Wall Street Zen raised Ovid Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $3.10.

Ovid Therapeutics Price Performance

Shares of NASDAQ:OVID traded down $0.0140 on Monday, hitting $0.9360. The company had a trading volume of 530,099 shares, compared to its average volume of 967,490. The company has a market cap of $66.56 million, a PE ratio of -1.77 and a beta of 0.20. The business has a 50 day moving average of $0.49 and a 200 day moving average of $0.43. Ovid Therapeutics has a 52-week low of $0.2425 and a 52-week high of $1.47. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.23.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in shares of Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company's stock valued at $53,000 after acquiring an additional 18,841 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Ovid Therapeutics in the 4th quarter valued at $65,000. XTX Topco Ltd bought a new stake in Ovid Therapeutics in the first quarter worth approximately $29,000. Renaissance Technologies LLC boosted its position in shares of Ovid Therapeutics by 142.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company's stock worth $101,000 after purchasing an additional 63,200 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Ovid Therapeutics during the 1st quarter valued at $37,000. 72.24% of the stock is owned by institutional investors and hedge funds.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.